stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Total debt
Denali Therapeutics Inc.'s total debt at the end of fiscal 2025 was $5.5M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $5.4M. Over the past ten years it has ranged from $5.5M (fiscal 2025) to $69.0M (fiscal 2019) — the current reading is the lowest in ten years. Denali Therapeutics Inc. ranks 282nd of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $5.5M | (1.48%) |
| FY2024 | $5.6M | (89.41%) |
| FY2022 | $53.0M | (10.17%) |
| FY2021 | $59.0M | (7.81%) |
| FY2020 | $64.0M | (7.25%) |
| FY2019 | $69.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $5.4M | (0.55%) |
| Jun 2026 | $5.5M | (0.53%) |
| Mar 2026 | $5.5M | (0.43%) |
| Dec 2025 | $5.5M | (0.40%) |
| 24 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| CELC Celcuity, Inc. compare | $753.2M |
| TLX Telix Pharmaceuticals Limited compare | $575.9M |
| VKTX Viking Therapeutics, Inc. compare | $250.7M |
| VRDN Viridian Therapeutics, Inc. compare | $242.2M |
| DYN Dyne Therapeutics, Inc. compare | $213.5M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $72.9M |
| DNLI Denali Therapeutics Inc. | $5.4M |
| IDYA IDEAYA Biosciences, Inc. compare | $2.1M |
| ELVN Enliven Therapeutics, Inc. compare | $445.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement